[go: up one dir, main page]

SMT201500245B - Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso - Google Patents

Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso

Info

Publication number
SMT201500245B
SMT201500245B SM201500245T SM201500245T SMT201500245B SM T201500245 B SMT201500245 B SM T201500245B SM 201500245 T SM201500245 T SM 201500245T SM 201500245 T SM201500245 T SM 201500245T SM T201500245 B SMT201500245 B SM T201500245B
Authority
SM
San Marino
Prior art keywords
irinotecan
liposome
preparation process
respective hydrochloride
hydrochloride
Prior art date
Application number
SM201500245T
Other languages
English (en)
Inventor
Xinyong Tong
Guofeng Lei
Chengxia Yu
Liang Chen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai Hengrui Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai Hengrui Pharm Co Ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of SMT201500245B publication Critical patent/SMT201500245B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
SM201500245T 2009-12-03 2015-10-09 Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso SMT201500245B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2009/075298 WO2011066684A1 (zh) 2009-12-03 2009-12-03 伊立替康或盐酸伊立替康脂质体及其制备方法

Publications (1)

Publication Number Publication Date
SMT201500245B true SMT201500245B (it) 2015-10-30

Family

ID=44114598

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500245T SMT201500245B (it) 2009-12-03 2015-10-09 Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso

Country Status (21)

Country Link
US (2) US20120282325A1 (it)
EP (1) EP2508170B1 (it)
JP (1) JP5645954B2 (it)
KR (2) KR20120089754A (it)
CN (1) CN102271659B (it)
AU (1) AU2009356132B2 (it)
BR (1) BR112012012151B8 (it)
CA (1) CA2782911C (it)
CY (1) CY1116811T1 (it)
DK (1) DK2508170T3 (it)
ES (1) ES2547698T3 (it)
HR (1) HRP20150911T1 (it)
HU (1) HUE027467T2 (it)
MX (1) MX2012005775A (it)
PL (1) PL2508170T3 (it)
PT (1) PT2508170E (it)
RU (1) RU2526114C2 (it)
SI (1) SI2508170T1 (it)
SM (1) SMT201500245B (it)
WO (1) WO2011066684A1 (it)
ZA (1) ZA201203316B (it)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935066B (zh) * 2011-08-16 2014-09-17 齐鲁制药有限公司 一种伊立替康脂质体制剂及其制备方法
DK2768484T3 (da) 2011-10-21 2019-10-07 Jazz Pharmaceuticals Res Llc Lyofiliserede liposomer
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
KR20140143838A (ko) * 2012-04-10 2014-12-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 비스-중합체 지질-펩티드 콘주게이트 및 이들의 나노입자
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN102697720B (zh) * 2012-06-29 2014-01-15 海南灵康制药有限公司 盐酸伊立替康脂质纳米粒注射剂
CN103181898B (zh) * 2012-11-23 2016-03-09 杭州师范大学 一种奥沙利铂脂质体及其应用
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
LT3138555T (lt) 2014-04-30 2021-03-25 Fujifilm Corporation Liposomų kompozicija ir jų gamybos būdas
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2016208742A1 (ja) * 2015-06-25 2016-12-29 参天製薬株式会社 注射剤
KR20180037210A (ko) 2015-08-20 2018-04-11 입센 바이오팜 리미티드 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법
KR102714060B1 (ko) 2015-08-21 2024-10-08 입센 바이오팜 리미티드 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법
NZ741291A (en) 2015-10-16 2022-10-28 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
ES2968415T3 (es) 2016-02-09 2024-05-09 Sun Pharmaceutical Ind Ltd Sistema de perfusión
CN107281102A (zh) * 2016-04-11 2017-10-24 江苏竞诺择生物医药科技有限公司 一种用于结直肠肿瘤治疗的药物微粒组合物
CN107456456A (zh) * 2016-06-03 2017-12-12 江苏恒瑞医药股份有限公司 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
JP6878473B2 (ja) * 2016-06-28 2021-05-26 キメリックス インコーポレイテッド ブリンシドフォビルの製剤
CN106109415B (zh) * 2016-07-26 2019-01-29 金华市人民医院 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用
RU2756837C2 (ru) * 2016-09-09 2021-10-06 Айрисис, Инк. Липосомальные противоопухолевые композиции
IL266198B2 (en) * 2016-10-28 2023-11-01 Servier Lab Liposomal formulation for use in cancer treatment
WO2018083470A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
WO2019244978A1 (ja) 2018-06-20 2019-12-26 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
CN109675047B (zh) * 2019-01-07 2020-12-04 中国科学院化学研究所 一种对具有游离羟基的化合物进行脂质体修饰的方法
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
US11273124B2 (en) * 2019-05-23 2022-03-15 Brown University Antifungal nanoparticles for targeted treatment of fungal infections
US12509559B2 (en) 2019-10-28 2025-12-30 Brown University Bacterial beta-lactamase responsive hydrogels
CN114177278A (zh) * 2021-10-18 2022-03-15 山东多美康生物医药有限公司 脂质体制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6355268B1 (en) * 1998-09-16 2002-03-12 Alza Corporation Liposome-entrapped topoisomerase inhibitors
PT1443900E (pt) * 2001-11-13 2012-08-01 Celator Pharmaceuticals Inc Composições de veículo lipídico com estabilidade melhorada no sangue
KR101223366B1 (ko) * 2004-05-03 2013-01-16 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
WO2005117878A1 (ja) * 2004-06-01 2005-12-15 Terumo Kabushiki Kaisha イリノテカン製剤
CN1326525C (zh) * 2004-11-26 2007-07-18 复旦大学 10-羟基喜树碱长循环脂质体及其冻干制剂
WO2007076117A2 (en) * 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
US7489990B2 (en) * 2006-07-17 2009-02-10 Fehr Stephen L Systems and methods for calculating and predicting near term production cost, incremental heat rate, capacity and emissions of electric generation power plants based on current operating and, optionally, atmospheric conditions
CN101019834A (zh) * 2006-12-31 2007-08-22 西安力邦医药科技有限责任公司 注射用7-乙基-10羟基喜树碱脂质体的制备方法
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
CA2681302C (en) 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物

Also Published As

Publication number Publication date
EP2508170A1 (en) 2012-10-10
HK1159482A1 (en) 2012-08-03
DK2508170T3 (en) 2015-09-21
AU2009356132A1 (en) 2012-06-21
PL2508170T3 (pl) 2015-12-31
CN102271659B (zh) 2013-09-18
JP5645954B2 (ja) 2014-12-24
PT2508170E (pt) 2015-10-16
US20120282325A1 (en) 2012-11-08
US20170189392A1 (en) 2017-07-06
KR20160140992A (ko) 2016-12-07
EP2508170A4 (en) 2014-01-15
BR112012012151A2 (pt) 2016-04-12
MX2012005775A (es) 2012-06-13
RU2012123875A (ru) 2014-01-20
US10022365B2 (en) 2018-07-17
JP2013512262A (ja) 2013-04-11
RU2526114C2 (ru) 2014-08-20
BR112012012151B8 (pt) 2021-05-25
WO2011066684A1 (zh) 2011-06-09
HRP20150911T1 (hr) 2015-10-23
CA2782911A1 (en) 2011-06-09
EP2508170B1 (en) 2015-07-29
BR112012012151B1 (pt) 2021-01-19
AU2009356132B2 (en) 2015-01-22
SI2508170T1 (sl) 2015-12-31
HUE027467T2 (en) 2016-10-28
KR101780915B1 (ko) 2017-09-21
ZA201203316B (en) 2013-11-27
KR20120089754A (ko) 2012-08-13
ES2547698T3 (es) 2015-10-08
CY1116811T1 (el) 2017-03-15
CN102271659A (zh) 2011-12-07
CA2782911C (en) 2016-08-23

Similar Documents

Publication Publication Date Title
SMT201500245B (it) Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso
PL2990421T3 (pl) Przeciwciała anty-ceacam1 oraz sposoby ich stosowania
PL2427212T3 (pl) Przeciwciała anty cd-100 i sposoby ich zastosowania
GB2471765B (en) Geopolymeric structural building units and methods of manufacture thereof
HUE036439T2 (hu) Antimikrobiális készítmények és azok alkalmazási módszerei
DK2419670T3 (da) Leveringsmetode og sammensætninger
PL3121280T3 (pl) Antysensowne kompozycje i sposoby ich wytwarzania i stosowania
EP2470485A4 (en) CERAMIC ISOLATOR AND METHODS OF USE AND MANUFACTURE
PL2299977T3 (pl) Liposomy do dostarczania leków i sposoby ich wytwarzania
IL232598A0 (en) Crystalline forms of vilzodone and vilzodone hydrochloride
EP2128240A4 (en) ALCOHOLIC BEVERAGE CONTAINING TOMATO JUICE AND PROCESS FOR PRODUCING THE SAME
DK2415800T3 (da) Hyperforgrenet polyoxyalkylenforbindelse og fremgangsmåde til deres fremstilling
BRPI0819704A2 (pt) Branqueador líquido estável em prateleira e processo de preparação deste
PT2504298T (pt) Preparação e purificação de iodoxanol
IL221991B (en) Polymorphic forms st-246 and methods of preparation
IL197655A0 (en) Emulsions and methods of their production
EP2408153A4 (en) FIRST RELAY SERVER AND SECOND RELAY SERVER
BR112014002804A2 (pt) revestimento e método de preparação do mesmo
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos
FI20105638A0 (fi) Kivipinnoitteen valmistus
IT1397894B1 (it) Dispositivo micromeccanico e procedimento per la produzione dello stesso
IT1394217B1 (it) Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1403286B1 (it) Procedimento per la preparazione di compresse comprendenti 5-idrossitriptofano e triptofano
IL219316A0 (en) Processes for the preparation of 5-lipooxygenase activating protein inhibitors and their intermediates
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF